- Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company, closed a $30m Series C financing
- The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners
- In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace
- The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP
- Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway
- The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need
